We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AARD
126
Aardvark Therapeutics
AARD
$144M
$208K 0.04%
+15,882
New +$198K
PBYI icon
127
CALL
Puma Biotechnology
PBYI
$404M
$201K 0.03%
33,800
-102,100
-75% -$542K
NEUP
128
Neuphoria Therapeutics
NEUP
$21M
$194K 0.03%
50,000
+28,548
+133% +$203K
PLRX icon
129
Pliant Therapeutics
PLRX
$64.4M
$177K 0.03%
+144,914
New +$218K
INO icon
130
CALL
Inovio Pharmaceuticals
INO
$55.7M
$174K 0.03%
+100,000
New +$220K
ONC
131
BeOne Medicines Ltd
ONC
$32.8B
$173K 0.03%
+7,500
New +$2.45M
FHTX icon
132
Foghorn Therapeutics
FHTX
$266M
$165K 0.03%
30,630
-19,370
-39% -$87.8K
TLPH icon
133
Talphera
TLPH
$66.4M
$156K 0.03%
+136,923
New +$165K
RVPH
134
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$140K 0.02%
+25,000
New +$278K
PRTC
135
DELISTED
PureTech Health
PRTC
$124K 0.02%
7,442
+118
+2% +$2.03K
LYEL icon
136
PUT
Lyell Immunopharma
LYEL
$317M
$117K 0.02%
+3,800
New +$85K
INBX icon
137
Inhibrx
INBX
$1.2B
$103K 0.02%
+1,299
New +$88.5K
EDSA icon
138
Edesa Biotech
EDSA
$49.2M
$76.7K 0.01%
+54,025
New +$106K
VTGN icon
139
CALL
VistaGen Therapeutics
VTGN
$9.89M
$70.5K 0.01%
106,500
+6,300
+6% +$22.8K
VTGN icon
140
VistaGen Therapeutics
VTGN
$9.89M
$66.2K 0.01%
100,000
-249,789
-71% -$902K
FLNA
141
PUT
Filana Therapeutics
FLNA
$48.8M
$21K ﹤0.01%
10,600
+700
+7% +$2.24K
ATYR
142
CALL
aTyr Pharma
ATYR
$47.6M
$12.1K ﹤0.01%
15,500
-113,200
-88% -$92.9K
ATYR
143
PUT
aTyr Pharma
ATYR
$47.6M
$9.24K ﹤0.01%
11,800
-64,400
-85% -$52.9K
JBIO
144
PUT
Jade Biosciences
JBIO
$1.2B
$2.97K ﹤0.01%
1,046
– –
APLT
145
CALL
DELISTED
Applied Therapeutics
APLT
$2.02K ﹤0.01%
20,200
+1,200
+6% +$762
ACAD icon
146
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-89,000
Closed -$1.9M
AGIO icon
147
CALL
Agios Pharmaceuticals
AGIO
$1.79B
– –
-222,100
Closed -$8.92M
ALEC icon
148
Alector
ALEC
$168M
– –
-136,023
Closed -$403K
ALKS icon
149
Alkermes
ALKS
$8.22B
– –
-72,079
Closed -$2.16M
AMLX icon
150
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-100,000
Closed -$1.36M
4 5
6
7 8

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.